A detailed history of Leverty Financial Group, LLC transactions in Exact Sciences Corp stock. As of the latest transaction made, Leverty Financial Group, LLC holds 4,000 shares of EXAS stock, worth $211,640. This represents 0.15% of its overall portfolio holdings.

Number of Shares
4,000
Holding current value
$211,640
% of portfolio
0.15%

Shares

6 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 16, 2024

BUY
$42.43 - $70.83 $169,720 - $283,320
4,000 New
4,000 $272,000
Q2 2023

Jul 27, 2023

SELL
$62.68 - $95.05 $9,402 - $14,257
-150 Reduced 3.61%
4,000 $375,000
Q4 2022

Jan 30, 2023

BUY
$30.35 - $53.15 $125,952 - $220,572
4,150 New
4,150 $205,000
Q2 2022

Jul 18, 2022

SELL
$35.61 - $76.23 $147,781 - $316,354
-4,150 Closed
0 $0
Q1 2022

Apr 20, 2022

BUY
$57.56 - $82.54 $8,634 - $12,381
150 Added 3.75%
4,150 $290,000
Q4 2021

Feb 09, 2022

BUY
$72.5 - $100.68 $290,000 - $402,720
4,000 New
4,000 $311,000

Others Institutions Holding EXAS

About EXACT SCIENCES CORP


  • Ticker EXAS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Diagnostics & Research
  • Shares Outstandng 176,960,000
  • Market Cap $9.36B
  • Description
  • Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX, a gene expression tests for...
More about EXAS
Track This Portfolio

Track Leverty Financial Group, LLC Portfolio

Follow Leverty Financial Group, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Leverty Financial Group, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Leverty Financial Group, LLC with notifications on news.